Tag Archives: Investment

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

VIDEO: Public Policies to Promote the Innovation Economy

SBIR Reauthorization Moves Forward

What can lawmakers do to make the US more competitive globally and encourage investment in groundbreaking R&D companies? Earlier today, the Coalition of Small Business Innovators held a forum at the National Press Club to discuss proposals that would do just that. Moderated by Paul Stimers, a partner with K&L Gates, the panel included Doug Doerfler, president and CEO of MaxCyte, Ed Mathers, a partner with venture capital firm New Enterprise Associates, Katherine Hamilton, policy Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Emerging Company Policy Deconstructed: Fostering Innovation Act (H.R. 2629)

scientists115x76

In a nutshell: Representative Michael Fitzpatrick (R-PA) introduced H.R. 2629, the Fostering Innovation Act, to update SEC filing status classifications for public companies and help ease regulatory burdens on emerging companies and reduce the bureaucratic hurdles and red tape that lengthen the time to bring cures from discovery to patient. Why you should care: SEC Rule 12b-2 establishes three classifications for public companies to determine their filing status, which include large accelerated filers (companies with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Emerging Company Policy Deconstructed: Small Cap Liquidity Reform Act (H.R. 3448)

87881842

In a nutshell: This bill, sponsored by Reps. Sean Duffy (R-WI) and John Carney (D-DE), will spur capital formation by increasing liquidity for emerging growth companies, including biotech innovators, that trade on the public market. Why you should care: Under current U.S. Securities and Exchange Commission (SEC) rules, all securities on the public market are priced in $0.01 increments. This minimum trading increment is known as the “tick size.” The switch to the standard tick Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Emerging Company Policy Deconstructed: Start-up Jobs and Innovation Act (S. 1658)

Cancer

In a nutshell: Senators Robert Menendez (D-NJ) and Pat Toomey (R-PA) introduced the Start-up Jobs and Innovation Act to spur capital formation for R&D-focused companies in the early stages of development. Why you should care: It can take over a decade and cost more than $1 billion to bring a single groundbreaking biotechnology treatment from laboratory bench to hospital bedside, and virtually the entire process is funded by private investment. The Start-up Jobs and Innovation Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,